safety profile of anti-cd19 car t-cell therapy axicabtagene ciloleucel
Published 6 years ago • 117 plays • Length 1:11Download video MP4
Download video MP3
Similar videos
-
3:43
safety and efficacy of ytb323, a car t-cell therapy, in r/r dlbcl
-
4:24
investigating production failure and out-of-specification production of car t-cell therapeutics
-
1:02
the use of car-t cell products in a real-world setting
-
10:00
2024eha | targeting cd7 car-t therapy shows efficacy and safety in treating r/r t-all/lbl patients
-
11:17
car-t cells: engineered cancer killers
-
2:53
understanding how patients relapse from car t-cell therapy
-
3:36
car t-cell therapy – redefining blood cancer treatment
-
3:10
universal car-t therapy for t-all
-
2:53
safety and efficacy of allogenic car-t cell treatment
-
4:10
car t-cell therapy for all
-
3:33
an overview of the car t-cell therapy story
-
2:05
the cost-effectiveness of car t-cell therapy
-
1:19
quality control in manufacturing car-t cell therapies
-
1:35
key mechanisms of resistance to car t-cell therapy
-
1:06
car t-cell manufacturing: the ucl group's experience
-
8:27
phase i trial of donor-derived cd7 car t-cells for t-all
-
1:40
overcoming antigen escape following cd19-directed car-t therapy
-
3:38
finding the expansion balance: car t-cell response markers identified from the trial of jcar017
-
1:08
point-of-care car t-cells
-
1:21
anti-cd22 car t-cell therapy for all: trial update, utility for salvage and cd19 status
-
1:24
the jacie model for centers administering car t-cell therapy